European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society

Lip, Gregory Y.H.; Heinzel, Frank R.; Gaïta, Fiorenzo; Juanatey, José Ramón González; Heuzey, J.-Y. Le; Potpara, Tatjana; Svendsen, Jesper Hastrup; Vos, Marc A.; Anker, Stefan D.; Coats, Andrew J.S.; Haverkamp, Wilhelm; Manolis, Antonis S.; Chung, Mina K.; Sanders, Prashanthan; Pieske, Burkert; Görenek, Bülent; Lane, Deirdre A.; Boriani, G; Linde, Cecilia; Hindricks, Gerhard; Tsutsui, Hiroyuki; Homma, Shunichi; Brownstein, Sheldon L.; Nielsen, Jens Cosedis; Lainščak, Mitja; Crespo-Leiro, María G.; Piepoli, Massimo F; Seferović, Petar; Savelieva, Irene

doi:10.1093/europace/euv191

Cited by 74 publications

(78 citation statements)

References 288 publications

(161 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Arrhythmogenicity is supposed to be elevated during ventricular remodeling 26. During the time of reverse remodeling, patients in our study presented a relevant risk for SCD given that 11 (7%) suffered from VT/VF during the study and received a life‐saving WCD therapy.…”

Section: Discussionmentioning

confidence: 79%

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study

Duncker

König

Hohmann

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundOptimal timing of implantation of an implantable cardioverter/defibrillator (ICD) after newly diagnosed heart failure is unclear given that late reverse remodelling may occur. We aimed to analyze left ventricular ejection fraction (LVEF) after diagnosis of an LVEF ≤35% during optimization of heart failure drug therapy.Methods and ResultsOne hundred fifty‐six patients with newly diagnosed LVEF ≤35% receiving a wearable cardioverter/defibrillator (WCD) were analyzed. WCD was prescribed for 3 months until first re‐evaluation. Indications for prolongation of WCD wearing period instead of ICD implantation were: (1) LVEF at 3‐month visit 30% to 35%; (2) increase in LVEF of ≥5% compared to the last visit; and (3) nonoptimized heart failure medication. Mean LVEF was 24±7% at diagnosis and 39±11% at last follow‐up (mean, 12±10 months). Whereas 88 patients presented a primary preventive ICD indication (LVEF ≤35%) at 3‐month follow‐up, only 58 showed a persistent primary preventive ICD indication at last follow‐up. This delayed improvement in LVEF was related to nonischemic origin of cardiomyopathy, New York Heart Association functional class at baseline, heart rate, better LVEF after 3 months, and higher dosages of mineralocorticoid receptor antagonist. Twelve appropriate WCD shocks for ventricular tachycardia/ventricular fibrillation occurred in 11 patients. Two patients suffered from ventricular tachycardia/ventricular fibrillation beyond 3 months after diagnosis.ConclusionsA relevant proportion of patients with newly diagnosed heart failure shows recovery of LVEF >35% beyond 3 months after initiation of heart failure therapy. To avoid untimely ICD implantation, prolongation of WCD period should be considered in these patients to prevent sudden cardiac death while allowing left ventricular reverse remodeling during intensified drug therapy.

show abstract

Section: Discussionmentioning

confidence: 79%

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study

Duncker

König

Hohmann

et al. 2017

JAHA

View full text Add to dashboard Cite

show abstract

“…W najnowszych wytycznych ESC dotyczących niewydolności serca [222] wprowadzono nową kategorię niewydolności serca z pośrednią frakcją wyrzutową (HFmrEF; LVEF 40-49%), choć dane na temat pacjentów z AF w tej grupie są ograniczone. Cele postępowania u wszystkich pacjentów z AF i współistniejącą niewydolnością serca, niezależnie od LVEF, obejmują zapobieganie niepomyślnym wynikom leczenia oraz utrzymywanie dobrej jakości życia [223]. Ogólne zasady leczenia AF nie różnią się między pacjentami z niewydolnością serca a innymi pacjentami, ale pewne kwestie zasługują na rozważenie.…”

Section: Nasilenie Objawów Związanychunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

Self Cite

2,380

4,206

View full text Add to dashboard Cite

“…Оптимальная ЧСС в покое у пациентов с ФП и ХСН не определена и находится в пределах от 60-100 ударов в минуту [52]. Согласно современным рекомендациям, БАБ являются препаратами первой линии для контроля ЧСС, несмотря на отсутствие влияния на прогноз [53]. К настоящему вре-мени получены данные двух метаанализов по примене-нию БАБ у пациентов систолической ХСН и ФП, которые показали отсутствие влияния терапии БАБ на прогноз в данной группе.…”

Section: кардиологияunclassified

Epidemiology and Management of Heart Failure Patients With Atrial Fibrillation

Zhirov¹,

Nv²,

Tereshchenko³

et al. 2015

Kardiologiia

View full text Add to dashboard Cite

Хроническая сердечная недостаточность (ХСН) и фибрилляция предсердий (ФП) являются наиболее распространенными состояниями в клинической практике. ХСН и ФП часто сочетаются друг с другом. Количество пациентов с ХСН и ФП неу-клонно растет с каждым годом. До настоящего времени ряд вопросов, касающихся тактики антикоагулянтной терапии этой группы пациентов, остается нерешенным. В данном обзоре представлены данные об уровне соблюдения клинических рекомендаций, распространенности длительной антикоагулянтной терапии у данной группы больных. Heart failure and atrial fibrillation are the most common cardiovascular conditions in clinical practice and frequently coexist. The number of patients with heart failure and atrial fibrillation is increasing every year. Nowadays the question of anticoagulant therapy for this category of patients is being discussed. In our review we summarized data on the guideline adherence and prevalence of long-term anticoagulant therapy in patients with atrial fibrillation and heart failure.

show abstract

European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society

Cited by 74 publications

References 288 publications

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Epidemiology and Management of Heart Failure Patients With Atrial Fibrillation

Contact Info

Product

Resources

About